Pilot Study for Measuring Molecular Biomarkers and Their Capacity to Characterize Radionuclide Therapy With Lu-177 DOTATATE) in Metastatic G1-G2 Neuroendocrine Midgut Tumors
Latest Information Update: 16 Apr 2025
At a glance
- Drugs Lutetium-(177Lu)-oxodotreotide (Primary)
- Indications Neuroendocrine tumours
- Focus Pharmacodynamics; Pharmacogenomic
- Acronyms GENEBIOLuNET
Most Recent Events
- 10 Apr 2025 Status changed from active, no longer recruiting to completed.
- 18 Sep 2023 Planned End Date changed from 1 Dec 2021 to 1 Dec 2025.
- 18 Sep 2023 Planned primary completion date changed from 1 Aug 2021 to 1 Dec 2023.